Washington, D.C. · Nonprofit
BIOTECHNOLOGY INNOVATION ORGANIZATION
BIOTECHNOLOGY INNOVATION ORGANIZATION (Washington, D.C.) receives grants from 2 organizations whose IRS filings report $323,700 to it, the largest being WE WORK FOR HEALTH ($250,000). 0 of them have funded it in more than one year.
- Revenue FY2024
- $118M
- Funders on record
- 2
- Grants received
- $324k
- Net assets
- $93M
What Biotechnology Innovation Organization does
Mission
The Biotechnology Innovation Organization (bio) represents approximately 1,000 companies and organizations in washington dc, state capitals, and international fora. Bio is founded on the principle that policy must nurture innovation in the life sciences to overcome challenges in health care, agriculture, industry, and the environment. Our members represent companies offering a spectrum of biotechnology applications across major sectors of the economy. Bio members also include universities, nonprofits, patient groups, and other organizations that play an important role in the future of the life sciences. Bio's activities are broken down into two programs - advocacy and services.
As stated on its FY2024 Form 990.
Programs
Advocacy: Biotechnology Innovation Organization (bio)'s advocacy efforts reflect the priorities identified by the bio board of directors and the three section governing boards.the board of directors focuses on issues of importance to all bio members, regardless of their size or technology. These cross-cutting advocacy accomplishments for the year are listed below: - safeguarded and advanced intellectual property protections, domestically and internationally.- fostered a dialogue about proactively advancing the socially responsible use of biotechnology.- promoted investment in government and academic research.- expanded outreach to foreign governments and international entities to educate on policy issues of importance to the biotechnology industry and to improve the investment and regulatory climate for biotech products.the health section advocacy accomplishments: - promoted healthcare policies that recognize both the promise and value of innovation.- advocated for a safe and predictable regulatory environment for value-based payment arrangements for drugs and biologics.- enhanced and protected patient access to innovative therapies and promoted the need for greater…
Services: bio's services include conferences and activities that bring advocacy accomplishments listed below:- safeguarded and advanced intellectual property protections, domestically and internationally.- fostered a dialogue about proactively advancing the socially responsible use of biotechnology.- promoted investment in government and academic research.- brought together industry stakeholders and investors for events ranging from the bio international convention to conferences for business development executives.the bio international convention attracts the most influential biotech and pharma attendees from 69 countries and 50 u.s. States, as well as the district of columbia and puerto rico and offers professional and business development opportunities. The net income from the convention supports our advocacy, public outreach, and other member service activities.the key elements of the bio international convention are educational programming, exhibition, the bio business forum, and networking events. These elements provide an opportunity for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to learn about recent…
The 2 programs described on its FY2024 Form 990, listed largest first by expense.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2020 to 2021, from $77M to $114M (+48%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 2 of the last 8 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
The chief executive listed changed between the FY2022 and FY2023 filings.
Who funds it, year by year
2022 → 2023: the base held at 1 funder, grant income fell $250k → $74k.
Left out of every figure on this page: $4.2M from one payer (the payer shares this organization's board, largest Pharmaceutical Research and Manufacturers of America). These are real filings, and they are not money BIOTECHNOLOGY INNOVATION ORGANIZATION raised.
From the IRS filings of BIOTECHNOLOGY INNOVATION ORGANIZATION’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
BIOTECHNOLOGY INNOVATION ORGANIZATION leans on a few funders — its largest provides 77% of grant income and the top three 100%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
100% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund BIOTECHNOLOGY INNOVATION ORGANIZATION.
Largest funder’s share by year: 2022 100% · 2023 100% — broadly stable.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Where its funders are
77% of BIOTECHNOLOGY INNOVATION ORGANIZATION's grant income comes from Washington, D.C. funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Government funding BIOTECHNOLOGY INNOVATION ORGANIZATION receives
Grants and contracts to this organization from federal (USASpending) and state checkbooks, reconciled to its EIN. $446k on record.
- Department of Defense$263k
- National Science Foundation$109k
- Department of Agriculture$28k
- Department of Health and Human Services$24k
- Department of Commerce$22k
Federal grants vs contracts are distinguished; state line items keep their reported category. Matched by name + geography (the BMF), so coverage is partial and precision-first.
Organizations like BIOTECHNOLOGY INNOVATION ORGANIZATION
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Washington, D.C.
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Governance
Screen this organization
A dated, signed PDF of the compliance screen for BIOTECHNOLOGY INNOVATION ORGANIZATION: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds BIOTECHNOLOGY INNOVATION ORGANIZATION?
- BIOTECHNOLOGY INNOVATION ORGANIZATION (Washington, D.C.) receives grants from 2 organizations whose IRS filings report $323,700 to it, the largest being WE WORK FOR HEALTH ($250,000). 0 of them have funded it in more than one year.
- How many funders does BIOTECHNOLOGY INNOVATION ORGANIZATION have?
- IRS filings report 2 organizations giving $323,700 in grants to BIOTECHNOLOGY INNOVATION ORGANIZATION.
- Who is the largest funder of BIOTECHNOLOGY INNOVATION ORGANIZATION?
- WE WORK FOR HEALTH is the largest funder on record, with $250,000 in grants. The full list of funders is on this page.
- How can an organization like BIOTECHNOLOGY INNOVATION ORGANIZATION find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Washington, D.C.. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 2 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing